San Francisco Dermatology, 350 Parnassus Ave, Suite 400, San Francisco, CA 94117, USA.
Dermatol Surg. 2012 Jul;38(7 Pt 2):1180-92. doi: 10.1111/j.1524-4725.2012.02473.x.
To assess the effectiveness and safety of small gel particle hyaluronic acid (SGP-HA) for lip augmentation.
Adults (n = 180; aged 18-65) scoring 1 (very thin) to 2 (thin) on the 5-point validated Medicis Lip Fullness Scale (MLFS) for the upper or lower lip were randomized (3:1) to SGP-HA (≤1.5 mL/lip) or no treatment. Co-primary effectiveness end points were blinded-evaluator MLFS score for upper or lower lip at week 8. Secondary end points (MLFS score, independent photographic review, Global Aesthetic Improvement Scale [GAIS], safety assessments) were measured throughout the study.
Statistically significantly more MLFS responders (≥1 grades of MLFS improvement at week 8) received SGP-HA (93% combined upper and lower lip responders [95% upper lip; 94% lower lip]) than no treatment (29% combined; p < .001). SGP-HA improved self-assessed combined lip GAIS (97% week 8; 74% week 24) significantly more than no treatment (0% throughout; p < .001). The SGP-HA group reported anticipated swelling (58%) and bruising (44%), 88% mild or 11% moderate severity, without unanticipated device adverse events.
SGP-HA is highly effective and well tolerated for lip augmentation. Statistically significant improvement was evident based on the MLFS at 8 weeks, with visible results reported in the majority of participants 6 months after treatment.
评估小凝胶颗粒透明质酸(SGP-HA)用于丰唇的效果和安全性。
成人(n=180;年龄 18-65 岁)的上唇或下唇经 Medis 唇部丰满度评分(MLFS)评估为 1(非常薄)至 2(薄)的患者,按 3:1 随机分组接受 SGP-HA(≤1.5mL/唇)或不治疗。主要疗效终点为第 8 周时上唇或下唇盲法评估者的 MLFS 评分。次要终点(MLFS 评分、独立照片评估、整体美观改善评分[GAIS]、安全性评估)在整个研究期间进行测量。
在第 8 周时,更多的 MLFS 应答者(MLFS 改善≥1 级)接受了 SGP-HA 治疗(93%的上唇和下唇联合应答者[95%的上唇;94%的下唇]),而非不治疗(29%的联合应答者;p<0.001)。与不治疗组相比(整个研究过程中均为 0%),SGP-HA 显著改善了自我评估的联合唇部 GAIS(97%在第 8 周;74%在第 24 周)(p<0.001)。SGP-HA 组报告预期肿胀(58%)和瘀伤(44%),88%为轻度或 11%为中度,没有意外的器械不良事件。
SGP-HA 用于丰唇效果显著且耐受性良好。在第 8 周时基于 MLFS 显示出明显的改善,治疗后 6 个月大多数患者报告了可见的效果。